AXSOME THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
AXSOME THERAPEUTICS, INC. (AXSM) reported Increase Decrease In Operating Lease Liability of -$1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$789.00K.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$608.00K, a 392.31% decline year-over-year.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$399.00K.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $208.00K.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$535.00K.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$422.00K, a 374.03% decline from fiscal 2023.
- AXSOME THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was $154.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|
| 2026-06-30 | -$789.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.40M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$608.00K 10-Q · filed 2026-05-04 | ||
| 2025-12-31 | -$535.00K 10-K · filed 2026-02-23 | ||
| 2025-06-30 | -$399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$191.00K 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $208.00K 10-Q · filed 2026-05-04 | ||
| 2024-12-31 | -$422.00K 10-K · filed 2026-02-23 | ||
| 2023-12-31 | $154.00K 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |